Case report: A promising neoadjuvant treatment option for individuals with locally advanced HER2-positive breast cancer involves the use of Pyrotinib Maleate in combination with Trastuzumab and Pertuzumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Case report: A promising neoadjuvant treatment option for individuals with locally advanced HER2-positive breast cancer involves the use of Pyrotinib Maleate in combination with Trastuzumab and Pertuzumab

Published:2024-07 Issue:14 Volume:10 Page:e34511
ISSN:2405-8440
Container-title:Heliyon
language:en
Short-container-title:Heliyon

Author:

Pan Chi,Ge Lan,Zhang Huifeng,Sang Kai,Zhou Jian,Yi Tongbo,Ni Qingtao

Funder

Nanjing Medical University

Publisher

Elsevier BV

Reference24 articles.

1. Cancer statistics, 2023;Siegel;CA A Cancer J. Clin.,2023

2. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020;Lei;Cancer Commun.,2021

3. Cancer treatment and survivorship statistics, 2022;Miller;CA A Cancer J. Clin.,2022

4. Soluble cytoplasmic expression and purification of immunotoxin HER2(scFv)-PE24B as a maltose binding protein fusion;Park;Int. J. Mol. Sci.,2021

5. Dnazyme catalyzed tyramide depositing reaction for in situ imaging of protein status on the cell surface;Xu;Theranostics,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monoclonal Antibody Therapies in Cancer Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP